Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Find the Specialty of Calligraphy: Dominating the Exquisite Art of Penmanship - 2Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
- 3Don't fall for it: These common tourist scams in Rome are easy to avoid if you know what you're looking for
- 4Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- 5Which salad do you believe is a definitive group pleaser? Vote!
- Weeks-Long Australian LNG Outage Will Further Tighten Supply
- Fact Check: Israeli Channel 13, Al Jazeera Did NOT Confirm Hezbollah Captured All Or Part Of Kiryat Shmona
- Investigating Free Cell Phones: What You Really want to Be aware
- Watch This Glacier Race into the Sea
- Insight: Pills, TikTok, weight-loss apps and the consumer-driven future of GLP-1s
- Exemplary Fragrances: A Manual for Notorious Scents
- James Webb Space Telescope finds strongest evidence yet for atmosphere around rocky exoplanet: 'It's really like a wet lava ball'
- Instructions to Explore the Universe of Vehicle Leases
- Genetic study identifies earliest-known dog, dating to 15,800 years ago
